Cellebrite DI (NASDAQ:CLBT) Issues Quarterly Earnings Results

Cellebrite DI (NASDAQ:CLBT) posted its earnings results on Thursday. The company reported $0.11 EPS for the quarter, topping analysts’ consensus estimates of $0.06 by $0.05, FiscalAI reports. The business had revenue of $131.14 million during the quarter, compared to analyst estimates of $131.50 million. Cellebrite DI had a return on equity of 16.04% and a net margin of 11.43%.

Here are the key takeaways from Cellebrite DI’s conference call:

• Q2 ARR and revenue fell short of expectations, with ARR rising 21% to $508 million but missing the low end of guidance. Several large government transactions slipped because of new procurement, foreign-entity permitting, and cloud/AI approval requirements.
• Cellebrite reduced its full-year 2026 outlook to $550 million–$560 million of ARR and $555 million–$561 million of revenue, citing slower Inseyets pricing and expansion, elongated deal cycles, and greater caution around large transactions.
• The company raised its full-year adjusted EBITDA outlook to $153 million–$159 million, or a 28% margin, while maintaining confidence in improving free cash flow as headcount remains essentially flat and FX headwinds eventually ease.
• New products are gaining traction: growth products contributed 25% of the sequential ARR increase, Genesis generated about $400,000 of ARR shortly after its launch, and Guardian secured a first major FedRAMP deal with a seven-figure initial order.
• Shiv Ramji became CEO effective immediately in an accelerated succession from Tom Hogan, reflecting the board’s preference for a product-centric leader focused on cloud-native platforms and AI; Cellebrite said the transition has the support of the management team.

Cellebrite DI Price Performance

Shares of CLBT traded up $0.34 on Friday, reaching $11.14. The company’s stock had a trading volume of 7,844,977 shares, compared to its average volume of 2,966,804. The stock has a market capitalization of $2.78 billion, a P/E ratio of 50.64, a PEG ratio of 1.34 and a beta of 1.18. The stock’s 50 day simple moving average is $14.47 and its two-hundred day simple moving average is $14.03. Cellebrite DI has a 12-month low of $9.58 and a 12-month high of $19.98.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the company. Needham & Company LLC decreased their target price on Cellebrite DI from $15.00 to $12.50 and set a “buy” rating for the company in a research report on Friday. Lake Street Capital decreased their price objective on shares of Cellebrite DI from $21.00 to $15.00 and set a “buy” rating for the company in a report on Friday. DA Davidson lowered their price objective on shares of Cellebrite DI from $22.00 to $15.00 and set a “buy” rating on the stock in a research report on Friday. JPMorgan Chase & Co. cut their target price on shares of Cellebrite DI from $20.00 to $16.00 and set an “overweight” rating for the company in a research report on Friday. Finally, Weiss Ratings lowered shares of Cellebrite DI from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Thursday. Five investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $16.70.

Insider Buying and Selling at Cellebrite DI

In other Cellebrite DI news, CEO Thomas E. Hogan sold 139,713 shares of the stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $15.39, for a total value of $2,150,183.07. Following the transaction, the chief executive officer directly owned 790,548 shares in the company, valued at approximately $12,166,533.72. This trade represents a 15.02% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO David Barter sold 41,734 shares of the business’s stock in a transaction on Wednesday, July 8th. The shares were sold at an average price of $16.38, for a total transaction of $683,602.92. Following the sale, the chief financial officer directly owned 334,219 shares of the company’s stock, valued at approximately $5,474,507.22. The trade was a 11.10% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 297,934 shares of company stock valued at $4,631,972. Insiders own 5.70% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in CLBT. Cooper Creek Partners Management LLC bought a new position in shares of Cellebrite DI during the 3rd quarter valued at approximately $55,999,000. Invesco Ltd. increased its stake in shares of Cellebrite DI by 58.6% in the third quarter. Invesco Ltd. now owns 5,560,196 shares of the company’s stock worth $103,030,000 after purchasing an additional 2,054,644 shares in the last quarter. Artisan Partners Limited Partnership purchased a new stake in shares of Cellebrite DI in the fourth quarter worth $25,871,000. Pertento Partners LLP raised its position in shares of Cellebrite DI by 28.2% during the 4th quarter. Pertento Partners LLP now owns 5,959,324 shares of the company’s stock valued at $107,447,000 after purchasing an additional 1,311,109 shares during the period. Finally, Wellington Management Group LLP purchased a new position in shares of Cellebrite DI during the 3rd quarter valued at $23,351,000. Institutional investors own 45.88% of the company’s stock.

Key Headlines Impacting Cellebrite DI

Here are the key news stories impacting Cellebrite DI this week:

• Positive Sentiment: Second-quarter adjusted EPS was $0.11, above the $0.05 consensus estimate cited by MarketBeat. Management also raised its adjusted EBITDA target, while subscription revenue continued to grow. Cellebrite second-quarter earnings report
• Positive Sentiment: Lake Street, JPMorgan, D.A. Davidson and Needham lowered their price targets but retained positive ratings: Buy or Overweight. Their revised targets range from $12.50 to $16, implying roughly 12% to 44% upside based on the provided reference price. Analyst price-target updates
• Positive Sentiment: Unusual options activity included nearly 20,000 call contracts, far above average volume, indicating speculative positioning for a potential rebound.
• Neutral Sentiment: Cellebrite completed a planned CEO transition, with Shiven Ramji succeeding Thomas E. Hogan effective August 13. The change may support a strategic reset, but investors face uncertainty during the leadership handoff. CEO succession announcement
• Negative Sentiment: The key catalyst for the selloff was lowered guidance. Third-quarter revenue is expected at $145 million-$148 million, below the $150.3 million consensus, while full-year revenue guidance of $555 million-$561 million trails the $568.1 million estimate. The company also reduced its 2026 ARR outlook. Cellebrite outlook announcement
• Negative Sentiment: Quarterly revenue of $131.14 million was slightly below the $131.87 million estimate. The earnings beat was therefore overshadowed by weaker growth indicators and the reset to management’s outlook.
• Negative Sentiment: Several law firms announced investigations into potential securities-law violations and whether prior projections and disclosures were accurate. The investigations are allegations, not findings, but add legal and reputational risk. Cellebrite investigation notice
• Negative Sentiment: Former CEO Thomas Hogan sold 139,713 shares worth approximately $2.15 million, reducing his holdings by about 15%. Although the sale may reflect the transition or personal financial planning, its timing weighs on investor sentiment. SEC insider trading filing

About Cellebrite DI

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.